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Psoriasis is an incurable autoimmune disease characterized by patches of
abnormal red, itchy and scaly skin. This work examined the modulation of
inflammation, hyperproliferation and immune cell markers following topi-
cal application of fish oil (FO) in comparison to the antipsoriatic agents,
betamethasone dipropionate (BD) and salicylic acid (SA), to GsdmA3Dfl/+
mice, a hair loss mutant which also exhibits epidermal hyperproliferation
akin to psoriasis. The mice were dosed with 100 mg of the test formulation
and after 10 days, the mice were sacrificed, skin sections excised and sub-
jected to immunohistochemical determination of COX-2, K17 and MAC-1;
and immunofluorescence of Ki-67. Unchanged expression of the proinflam-
matory enzyme COX-2 was observed in all treatments, suggesting the non-
involvement of COX-2 in the aetiology of cutaneous aberration seen in
GsdmA3Dfl/+ mice. Intense staining of K17 and MAC-1 in the FO-treated
group mirrored the epidermal thickening seen observed in live mice by
optical coherence tomography (OCT). The ratio of Ki-67-positive nuclei
per 100 basal cells indicated that hyperproliferation of keratinocytes
occurred in FO-treated mice and the opposite was true for BD-treated
mice. There was a positive correlation (R2 0.995) between Ki-67 and the
epidermal thickness data observed previously. In all immunochemical pro-
cedures, the combined BD, SA and FO formulation did not show any sig-
nificant difference with the control group, reflecting observations seen
previously. In conclusion, the epidermal changes observed following topical
FO treatment on GsdmA3Dfl/+ mice involves an increase in cellular prolif-
eration and macrophages, although COX-2 does not appear to play an
important role.
Psoriasis is an autoimmune disease characterized by
patches of abnormal red, itchy and scaly skin. It typi-
cally presents with red patches with white scales on top
with the areas of the body most commonly affected
being the back of the forearms, shins, around the navel
and the scalp. Plaque psoriasis accounts for about 90%
of cases. There is currently no cure for psoriasis
although drug therapy can help control the symptoms.
One promising developmental treatment involves fish
oil (FO), which is particularly rich in omega-3 polyun-
saturated fatty acids, most notably eicosapentanoic acid
(EPA) and docosahexaenoic acid (DHA). The benefits
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of FO supplementation in improving inflammatory skin
conditions have been extensively documented [1] and
efforts are in progress to develop an efficacious topical
FO formulation [2] for skin diseases such as psoriasis.
The effects of topically applied fish oil and other antip-
soriatic agents on the epidermal thickness of the
GsdmA3Dfl/+ mouse, with a phenotype that exhibits
some characteristics of psoriasis, were recently investi-
gated using optical coherence tomography (OCT) and
H&E staining [3]. The GsdmA3Dfl/+ mouse is a sponta-
neous mutant which exhibits a predictable destruction
of hair follicles arising from dysfunctional sebaceous
glands and altered hair cycle [4]. GsdmA3Dfl/+ mouse
was chosen for both the previous and current study
with view of proposing it as a new animal model for
psoriasis; the mutant exhibiting similarities to other
established models, such as asebia [5]. It was found that
topical treatment with the agents produced significant
changes in the thickness of the GsdmA3Dfl/+ mouse epi-
dermis over the duration of the study, treatment with
FO in particular causing an increase in epidermal thick-
ness and the BD-treated group showing significantly
reduced epidermal thickness; and epidermal thicknesses
were unchanged relative to control in the group treated
with a combined formulation of BD and FO [3]. In the
current study the investigations focused on finding a
link between the earlier findings with markers of cellular
proliferation, and also the protein and cells of the
immune system.
Cyclooxygenase 2 (COX-2) is one of the main
enzymes involved in the production of inflammatory
mediators or eicosanoids within the arachidonic acid
(AA) cascade, otherwise known as the inflammation
cascade. The products of this cascade, such as leuko-
triene, prostaglandin and thromboxane, help to protect
the body from injury and act in response to noxious
stimuli [6]. Prolonged inflammatory processes have
been implicated as the main cause of diseases, includ-
ing inflammatory skin diseases such as psoriasis [7].
Ki67 is an antigen produced by the gene MKI67
which is found to be expressed in the active phases of
the cell cycle, namely the G1, G2 and S phase in all
cells. It is totally absent during the resting (G0) phase
[8]. This strict association makes Ki67 a useful marker
for cell growth and division [9], and has been extre-
mely useful in the detection of tumours and other
forms of malignancies [10]. In normal epidermis, it is
expressed weakly in the basal and suprabasal layers,
while in psoriatic epidermis, Ki67 is distributed
throughout all the layers of the epidermis [11].
K17 is one of the numerous epithelial-associated
keratins, which are classified as Type I and Type II
keratins. K17, along with other Type I keratins are
acidic in nature, while Type II keratins such as K1–K5
are basic to neutral [12]. In normal conditions, K17 is
only expressed in the nail bed, hair follicles, sebaceous
glands, internal epithelia and developing interfollicular
epidermis [13]. However, in psoriatic lesions, there is
an increase in suprabasal K17 expression concurrent
with overexpression of K16 [14]. The increase in K17
is attributed to the rise seen in the levels of IFN-c in
psoriatic skin, both of which are believed to be con-
tributing factors to the development of psoriasis [13].
Macrophage-1 antigen (MAC-1, also known as
CR3; integrin alphaMbeta2, ITGAM) is a complement
receptor consisting of CD11b and CD18. It has an
affinity towards complements C3b and C4b. MAC-1 is
expressed on the cells of the innate immune system,
such as macrophages, monocytes, neutrophils and nat-
ural killer cells [15]. Identification of C3b and C4b on
foreign cells facilitates phagocytosis and the subse-
quent destruction of the foreign cells by the MAC-1
positive cells. As widely agreed, there is an accumula-
tion of inflammatory/immune cells in both the dermal
and epidermal layers of the psoriatic skin. These
include lymphocytes and also cells of the innate
immune system, such as neutrophils [16].
The aim of the current work was therefore to use
immunohistochemical methodology to determine
changes in the epidermis of the mice after topical treat-
ment with FO and common antipsoriatics, with regard
to inflammatory markers and/or mediators.
Materials and methods
Materials
Tissue-Tek O.C.TTM Compound (OCT) was obtained from
Sakura Finetek Europe B.V. Antibody towards Ki67 clone
MM1 (lot 111849) was obtained from Novocastra Labora-
tories (Newcastle, UK). Alexa Fluor 488 goat anti-(mouse
IgG) (lot 412441) and 40,6-diamidino-2-phenylindole were
purchased from Invitrogen (Paisley, UK). Hydromount
aqueous nonfluorescing mounting medium (lot 030805) was
from National Diagnostics (Atlanta, GA, USA). Vectas-
tainTM avidin-biotin complex (ABC) reagent (lot V0310)
was from Vector Labs Inc. (Burlingame, CA, USA). Don-
key serum (D9663), goat serum (G9023, lot SLBH1350V),
1,4-diazabicyclo [2.2.2] octane (DABCO) solution and
phosphate buffer saline sachets were purchased from
Sigma-Aldrich (Gillingham, UK). COX-2 (#4842, lot
123241) and MAC-1 CD11b rat anti-mouse antibody
(#550282, lot 98414) were from Cell Signalling Technology
(Danvers, MA, USA) and Pharmingen, BD Bioscience
(Oxford, UK) respectively. Biotinylated anti-rat (NA935,
lot 345191) and anti-rabbit (NA934, lot 372217) antibodies
were both obtained from GE Healthcare (Amersham, UK)
828 FEBS Open Bio 6 (2016) 827–834 ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Effect of fish oil on epidermal hyperproliferation M. H. Zulfakar et al.
and K17 antibody was produced in-house. All other
reagents were of analytical grade or equivalent.
Topical treatment of GsdmA3Dfl/+ mice
GsdmA3Dfl/+ mice were divided into four treatment groups
and treated with BD + SA (I), FO + SA (II),
BD + FO + SA (III) and blank ointment base (IV, control)
[3]. Each treatment group consisted of five mice of mixed
genders to offset any possible variation in response. All mice
were between 20 and 22 weeks of age, a stage where hair fol-
licle destruction is complete. One hundred milligrams of for-
mulation was topically applied on the dorsal area for
10 days, after which the mice were sacrificed and the skin of
the treated area excised and embedded in OCT media.
Immunohistochemical determination of COX-2,
K17 and MAC-1
Frozen slides were fixed in dried acetone for 15 min. Block-
ing was carried out in 5% normal serum in PBS for 20 min
according to the species the secondary antibodies were raised
in. For COX-2 and K17, it was donkey serum and goat
serum for MAC-1. Primary antibodies for COX-2 (1 in 50
dilution), K17 (1 in 500 dilution) and MAC-1
(1.25 lgmL1, 1 in 100 dilution) were applied to the section
for 1 h at room temperature or overnight (COX-2). Incuba-
tion with biotinylated 2° antibody (anti-rabbit for COX-2
and K17, anti-rat for MAC-1) was at 1 : 200 dilutions (in
PBS) for 30 min. Next, the slides were incubated with
VectastainTM avidin-biotin complex (ABC) reagent, again
for 30 min. Development of colour with DAB/H2O2 was
carried out for 10 min, and the slides dehydrated and
mounted with Distyrene plasticizer xylene (DPX) mountant.
Three skin sections were analysed from each mouse.
Immunofluorescence analysis of Ki67
Frozen OCT-embedded tissue sections (7 lm) were fixed in
4% paraformaldehyde for 15 min, followed by rinsing in
PBS for 5 min. The skin sections were then blocked with
5% w/v BSA in PBS for 30 min and incubated with primary
antibody for Ki67 (diluted 1 : 50 in PBS with 5% w/v BSA)
at 4 °C overnight. The following day, the slides were washed
39 with PBS/0.1% v/v Triton X100, then incubated with
anti-mouse immunoglobulin conjugated to Alexa 488 diluted
1 : 500 in PBS for 30 min. After washing with PBS/0.1%
Triton X100, DAPI diluted 1 in 5000 (in PBS) was applied
before mounting in HydromountTM. The ratio of dividing
cells was obtained by counting the number of positive nuclei
over a distance of 700 basal cells. A higher ratio indicates an
increase in Ki67, that is, an increase in cellular proliferation,
and vice versa.
Results
COX-2
Figure 1 revealed no appreciable difference in COX-2
immunoreactivity, taking into account the change in
I II
III IV
50 µm
Fig. 1. IHC staining for COX-2 at 209
magnification: I (BD + SA), II (FO + SA), III
(BD + FO + SA), and IV (control, blank
ointment base). The intensity of staining
was relatively unchanged in all treatment
groups.
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thickness observed with the different treatments, sug-
gesting that COX-2 does not play a significant role in
the development of the phenotypic changes seen in
GsdmA3Dfl.
K17
The expression of K17, as indicated in Fig. 2, mirrored
the changes seen in the epidermal thickness with the
different treatments. Elevated K17 was observed in the
FO-treated group, consistent with the gross increase in
the thickness of the epidermis. On the other hand, the
reduction in K17 staining with BD-treated group
(compared to control) supported the thinning seen pre-
viously in live GsdmA3Dfl/+ mice by OCT [3]. As sta-
ted earlier, the relative levels of K17 for the combined
BD + FO + SA, and control did not differ signifi-
cantly.
Ki67
Visual determination of positive nuclei from the
images shown in Fig. 3 showed an increased presence
of Ki67 in the sections treated with FO, again reflect-
ing the increased thickness of the epidermis. The anti-
gen was weakly expressed in the basal layers of the
BD-treated sections, and with the combined formula-
tion (III) the expression was comparable to that of the
control. Quantitatively, the ratios of Ki67 positive cells
over total basal cells were 0.16, 0.70, 0.21 and 0.23 for
I, II, III and IV (Fig. 4). Both I and II ratios showed
a statistically significant difference compared to con-
trol, with P 0.0415 and 0.0001 (Kruskall–Wallis post
test), respectively. The ratio for III was not significant
compared to control, with P 0.5732. Figure 5 is a plot
of Ki67 ratio versus epidermal thickness and shows R2
0.995, indicative of a correlation between epidermal
thickness and the expression of Ki67.
MAC-1
The IHC staining for MAC-1 is shown in Fig. 6. In
the control sections, the MAC-1-positive immune cells
were observed to be localized throughout the dermis,
although particularly concentrated close to the epider-
mis and at the bottom of the dermis. Treatment with
BD, a potent corticosteroid resulted in decreased pres-
ence of MAC-1-positive cells, especially near to the
epidermis. A small amount of MAC-1 remained,
although confined to the lower parts of the dermis,
probably in areas remote from where the topical treat-
ments had accumulated. The same was also observed
with the combined formulation (III). The treatment
with FO (II), however, did not reduce MAC-1 as
expected – in fact, it appeared to be increased com-
pared to control.
I II
III IV
50 µm
Fig. 2. IHC staining for K17 at 209
magnification: I (BD + SA), II (FO + SA), III
(BD + FO + SA), and IV (control, blank
ointment base). The intensity of the
staining mirrored the change in epidermal
thickness, evidenced by the highly intense
staining seen with FO-treated group (II)
and the pale staining observed in the
BD-treated group (I).
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Discussion
It was previously reported that levels of COX-2 and
COX-2-mediated arachidonic acid derivatives in
GsdmA3Dfl/+ mice were not significantly different
from those in wild-type mice [17]. The findings of the
study confirmed this, as there were no noticeable dif-
ferences in the staining intensity for all the treatment
groups. Therefore, we conclude any initial phenotypic
changes observed in the untreated mice, and the result-
ing post-treatment changes, were not caused by
COX-produced inflammatory mediators. The rationale
behind the selection of COX-2 for analysis stemmed
from the fact that products of COX-2 such as inter-
leukin-6, interleukin-12, TNF-a, and INF-c were
reported to be elevated in psoriatic lesions and in the
serum of psoriatic patients [18], although the specific
arrays of mediators are unable to be determined as
yet. Furthermore, evidence supported the presence of
COX-2 in both the suprabasal and basal layers of the
epidermis of psoriatic lesions [19].
I II
III IV
Fig. 3. Immunofluorescent staining for
Ki67 at 209 magnification: I (BD + SA), II
(FO + SA), III (BD + FO + SA), and IV
(control, blank ointment base); scale bar
20 lm. Nuclei positive for Ki67 are shown
in bright green, while negative cells are in
blue. Ki67 was highly expressed in mice
treated with FO (II). In all cases Ki67 was
only found to be expressed at the basal
layer of the epidermis.
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Fig. 4. Ratio of Ki67-positive cells per 100 epidermal basal cells: I
(BD + SA), II (FO + SA), III (BD + FO + SA), and IV (control, blank
ointment base), n = 15  SD. *P < 0.05. The increase in Ki67
ratio with FO treatment (II) corresponded to an increase in
epidermal thicknesses of the mice within the group. The opposite
was seen with BD treatment (I).
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Fig. 5. Plot of Ki67 ratio versus epidermal thickness (n = 15  SD).
A positive correlation between increased epidermal thickness and
the ratio of nuclei positive for Ki67 expression, signifying
hyperproliferation.
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In relation to the earlier study [3], the increase in
epidermal thickness with topical FO treatment
appeared to correlate with the increase in the expres-
sion of K17 and Ki67, both hyperproliferation mark-
ers. As mentioned earlier, Ki67 is only expressed
during the active phase of the cell cycle, that is, during
cellular division. This confirmed that the increased epi-
dermal thickness due to the presence of the FO was
due to hyperproliferation of keratinocytes, rather than
cellular enlargement or oedema resulting from the for-
mulations.
The apparent increase in macrophage infiltration
(MAC-1) was in contrast to the anti-inflammatory
activity of FO reported in numerous publications
although it might explain the increased epidermal
growth seen with FO application. The anti-inflamm-
matory activity of FO is attributed mainly to the pres-
ence of the omega-3 fatty acids, EPA and DHA.
Indeed, several trials with fish oil and/or the fatty
acids (in particular EPA) have proven the benefits of
fish oil in improving inflammatory skin diseases, such
as psoriasis [20,21]. Incorporation of EPA into cellular
membranes (through ingestion or application) and its
subsequent release results in several possible outcomes:
displacement of arachidonic acid (AA) (precursor of
many ‘proinflammatory’ eicosanoids) resulting in
reduced AA tissue concentration, competitive inhibi-
tion of AA-derived eicosanoids production by the
cyclooxygenase and lipoxygenase enzymes, and direct
antagonism of AA-derived eicosanoids action. Further-
more, EPA-derived eicosanoids such as leukotriene b5,
thromboxane a3 and prostaglandin E3 are less potent
inflammatory mediators as opposed to their AA-
derived counterparts, resulting in amelioration and
reduced extent of the inflammation process [22].
Thus, the result from this study was unexpected.
One possible explanation is that the immune cells were
reacting to other components of the oil, or perhaps an
allergic response to the fish oil. Sensitivity towards
topical application of fish oil has been reported in clin-
ical trials with psoriatic patients [21]. In a clinical trial
using FO applied topically to patients, marked irrita-
tion and a burning sensation were observed in the pla-
ques of one psoriatic patient with concurrent Hansen’s
disease. However, the symptoms disappeared 2 weeks
after completing the 4 weeks of topical therapy. It is
not known whether the same might be observed with
the mice, had the treatment been continued longer
than the 10 days of this study.
Increase in MAC-1 supports earlier reports of
increased infiltration of immune cells in the dermis of
GsdmA3Dfl/+ mice [17]. This, along with the observed
epidermal hyperproliferation, could be phenotype spe-
cific. However, similar observations were made in ear-
lier studies involving a animal models of epidermal
hyperproliferation, the condition arising from a
I
III IV
II
Fig. 6. IHC staining for MAC-1 antigen at
109 magnification: I (BD + SA), II
(FO + SA), III (BD + FO + SA), and IV
(control, blank ointment base); scale bar
50 lm. The presence of MAC-1 was
confirmed with the brown staining seen in
the sections. Note the intense staining
seen with II and IV, and the opposite with
the BD-containing treatment group (I and
III).
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deficiency of essential fatty acids [23,24]. It was found
that the epidermal thickening was successfully reversed
with linoleic acid (LA) supplementation, whereas FO
rich in omega-3 fatty acids such as EPA and DHA
only aggravated the condition. This was attributed to
the inhibition of 13-hydroxyoctadecanoic acid (13-
HODE) synthesis by DHA (a major component of
FO); 13-HODE believed to be crucial in maintaining
normal functions of the epidermis.
13-HODE is the major product of LA metabolism
by epidermal 15-lipoxygenase (15-LOX). LA, classified
as an essential fatty acid (EFA), is unable to be syn-
thesized by the body and obtainable only through diet-
ary means. The role of 13-HODE in governing
epidermal hyperproliferation and differentiation is
believed to involve the formation of a novel 13-
HODE-containing diacylglycerol (13-HODE-DAG)
[25]. This molecule selectively inhibits epidermal pro-
tein kinase C-a and –b, with the b isozyme specifically
elevated in the guinea pig model, suggesting a primary
role. This inhibitory effect on PKC highlighted the
importance of 13-HODE in the epidermis.
The above finding also provided great insight into
the epidermal changes in diseased states such as psori-
asis. Significantly lower levels of 13-HODE were
reported in psoriatic lesions, and the effect on epider-
mal phospholipids, that is, incorporation of 13-HODE
to DAG is thought to contribute to the antipsoriatic
effects of 15-LOX and its product. Furthermore, in
work with a mouse model for bullous congenital
ichthyosiform erythroderma (BICE which, like the
GsdmA3Dfl/+ genotype, exhibits epidermal thickening,
acanthosis and focal keratosis), it was concluded that
hyperproliferation of keratinocytes was only partly
responsible and other mechanisms yet undefined are
likely to be involved [26].
Conclusions
Overall, evidence from immunostaining of the different
proteins and markers leads to several conclusions.
First, the relatively unchanged levels of COX-2 expres-
sion in all treatment groups suggest a noninvolvement
of COX-2 in the aetiology of the GsdmA3Dfl/+ pheno-
type. Although COX-2 is a major component in the
inflammatory cascade, and there is evidence to suggest
that the destruction of hair follicles and the epidermal
changes are immune-driven, other mediators may play
a larger role in this particular mutation. This will also
explain why, in light of the inhibitory effect on COX-2
and its product by fish oil, it did not appear to reverse
the epidermal thickening; on the contrary the opposite
was seen. This leads to the second conclusion –
increased expression of Ki67 and K17, both markers
associated with hyperproliferation, corresponded to
the epidermal thickening seen with fish oil treatment.
Although not determined in this study, the similarities
observed with several published studies in animal mod-
els points to the effect of FO on important epidermal
mediators such as 13-HODE and may present a chal-
lenge in developing a functional topical formulation
containing FO and/or omega-3 fatty acids for condi-
tions such as psoriasis and eczema.
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